- Home
- POAI vs PATK Comparison
POAI vs PATK Comparison
Compare POAI & PATK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POAI
- PATK
- Stock Information
- Founded
- POAI 2002
- PATK 1959
- Country
- POAI United States
- PATK United States
- Employees
- POAI 35
- PATK N/A
- Industry
- POAI Industrial Specialties
- PATK Auto Parts:O.E.M.
- Sector
- POAI Health Care
- PATK Consumer Discretionary
- Exchange
- POAI Nasdaq
- PATK Nasdaq
- Market Cap
- POAI 9.9M
- PATK N/A
- IPO Year
- POAI N/A
- PATK N/A
- Fundamental
- Price
- POAI $1.30
- PATK $78.28
- Analyst Decision
- POAI Hold
- PATK Strong Buy
- Analyst Count
- POAI 1
- PATK 9
- Target Price
- POAI N/A
- PATK $102.07
- AVG Volume (30 Days)
- POAI 8.1M
- PATK 361.2K
- Earning Date
- POAI 05-13-2025
- PATK 05-01-2025
- Dividend Yield
- POAI N/A
- PATK 2.39%
- EPS Growth
- POAI N/A
- PATK N/A
- EPS
- POAI N/A
- PATK 4.11
- Revenue
- POAI $1,623,817.00
- PATK $3,715,683,000.00
- Revenue This Year
- POAI $486.27
- PATK $8.30
- Revenue Next Year
- POAI $65.50
- PATK $6.51
- P/E Ratio
- POAI N/A
- PATK $19.49
- Revenue Growth
- POAI N/A
- PATK 7.14
- 52 Week Low
- POAI $0.55
- PATK $67.72
- 52 Week High
- POAI $3.06
- PATK $98.90
- Technical
- Relative Strength Index (RSI)
- POAI 48.03
- PATK 30.46
- Support Level
- POAI $1.26
- PATK $82.12
- Resistance Level
- POAI $1.58
- PATK $89.13
- Average True Range (ATR)
- POAI 0.21
- PATK 2.84
- MACD
- POAI 0.01
- PATK -0.55
- Stochastic Oscillator
- POAI 16.13
- PATK 9.59
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.